How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,768 results for

Hypertension Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Congenital lobar emphysema: A rare cause of hypertension (PubMed)

Congenital lobar emphysema: A rare cause of hypertension Congenital lobar emphysema is a rare disease, which is characterized by pulmoner hyperinflation. Depending on the degree of bronchial obstruction, the clinical presentation may be variable. We report a rare case with congenital lobar emphysema in a 38-days-old male infant who presented with severe respiratory distress and hypertension. Air trapping in the left upper lung and significant mediastinal shift to the right were observed (...) on the chest x-ray. Emphysematous changes were detected on the thorax computed tomography and considered as congenital lobar emphysema. The upper left lobectomy was successfully performed by pediatric surgeons. On postoperative follow up, no sign of respiratory distress occured and the patient was normotensive. In this report, a case with congenital lobar emphysema, which is a rare cause of respiratory distress and hypertension is discussed.

Full Text available with Trip Pro

2016 Saudi medical journal

162. ROMK expression remains unaltered in a mouse model of familial hyperkalemic hypertension caused by the CUL3Δ403‐459 mutation (PubMed)

ROMK expression remains unaltered in a mouse model of familial hyperkalemic hypertension caused by the CUL3Δ403‐459 mutation Familial hyperkalemic hypertension (FHHt) is a rare inherited form of salt-dependent hypertension caused by mutations in proteins that regulate the renal Na(+)-Cl(-) cotransporter NCC Mutations in four genes have been reported to cause FHHt including CUL3 (Cullin3) that encodes a component of a RING E3 ligase. Cullin-3 binds to WNK kinase-bound KLHL3 (the substrate (...) recognition subunit of the ubiquitin ligase complex) to promote ubiquitination and proteasomal degradation of WNK kinases. Deletion of exon 9 from CUL3 (affecting residues 403-459, CUL3(Δ403-459)) causes a severe form of FHHt (PHA2E) that is recapitulated closely in a knock-in mouse model. The loss of functionality of CUL3(Δ403-459) and secondary accumulation of WNK kinases causes substantial NCC activation. This accounts for the hypertension in FHHt but the origin of the hyperkalemia is less clear. Hence

Full Text available with Trip Pro

2016 Physiological reports

163. Placental Hypoxia During Early Pregnancy Causes Maternal Hypertension and Placental Insufficiency in the Hypoxic Guinea Pig Model (PubMed)

Placental Hypoxia During Early Pregnancy Causes Maternal Hypertension and Placental Insufficiency in the Hypoxic Guinea Pig Model Chronic placental hypoxia is one of the root causes of placental insufficiencies that result in pre-eclampsia and maternal hypertension. Chronic hypoxia causes disruption of trophoblast (TB) development, invasion into maternal decidua, and remodeling of maternal spiral arteries. The pregnant guinea pig shares several characteristics with humans (...) blood vessels by TB cells. In summary, this animal model of placental HPX identifies several aspects of abnormal placental development, including increased TB proliferation and decreased migration and invasion of TBs into the spiral arteries, the consequences of which are associated with maternal hypertension and fetal growth restriction.© 2016 by the Society for the Study of Reproduction, Inc.

Full Text available with Trip Pro

2016 Biology of reproduction

164. Infantile Hepatic Hemangioendothelioma: An Uncommon Cause of Persistent Pulmonary Hypertension in a Newborn Infant (PubMed)

Infantile Hepatic Hemangioendothelioma: An Uncommon Cause of Persistent Pulmonary Hypertension in a Newborn Infant Multifocal and diffuse infantile hepatic hemangioendotheliomas commonly present with signs of high-output congestive heart failure. In addition, prolonged persistent pulmonary overcirculation eventually leads to the development of pulmonary hypertension at a later age. We report a 2-day old, full-term infant with multifocal, large infantile hepatic hemangioendothelioma, who (...) presented with an early onset of pulmonary hypertension, managed successfully with supportive care and systemic therapy directed toward the involution of infantile hepatic hemangioendothelioma.

Full Text available with Trip Pro

2016 AJP Reports

165. Free-Floating, Pigmented Cysts in the Anterior Chamber Causing Ocular Hypertension (PubMed)

Free-Floating, Pigmented Cysts in the Anterior Chamber Causing Ocular Hypertension The aim of this study was to describe the clinical and histopathological features of a 36-year-old male with hundreds of recurrent, unilateral, free-floating, pigmented cysts in the anterior chamber causing ocular hypertension.The patient was referred to ocular oncology for blurry vision of the right eye and was found to have myriad pigmented, free-floating cysts in the anterior chamber and heavy pigmentation

Full Text available with Trip Pro

2016 Ocular oncology and pathology

166. miR-138 and miR-25 Downregulate MCU, Causing Pulmonary Arterial Hypertension's Cancer Phenotype. (PubMed)

miR-138 and miR-25 Downregulate MCU, Causing Pulmonary Arterial Hypertension's Cancer Phenotype. Pulmonary arterial hypertension (PAH) is an obstructive vasculopathy characterized by excessive pulmonary artery smooth muscle cell (PASMC) proliferation, migration, and apoptosis resistance. This cancer-like phenotype is promoted by increased cytosolic calcium ([Ca2+]cyto), aerobic glycolysis, and mitochondrial fission.To determine how changes in mitochondrial calcium uniporter (MCU) complex (MCUC

Full Text available with Trip Pro

2016 American Journal of Respiratory and Critical Care Medicine

167. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (PubMed)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also increase adverse events. The optimal blood pressure target in people (...) with hypertension and established cardiovascular disease remains unknown.To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/ 90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease).The Cochrane Hypertension Information Specialist searched the following

Full Text available with Trip Pro

2017 Cochrane

168. Blood pressure targets for hypertension in older adults. (PubMed)

Blood pressure targets for hypertension in older adults. Eight out of 10 major antihypertensive trials in older adults attempted to achieve a target systolic blood pressure (BP) less than 160 mmHg. Collectively these trials demonstrated benefit for treatment, as compared to no treatment, for an older adult with BP greater than 160 mmHg. However an even lower BP target of less than 140 mmHg is commonly applied to all age groups. At the present time it is not known whether a lower or higher BP (...) target is associated with better cardiovascular outcomes in older adults.To assess the effects of a higher (less than 150 to 160/95 to 105 mmHg) BP target compared to the lower BP target of less than 140/90 mmHg in hypertensive adults 65 years of age or older.The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to February 2017: the Cochrane Hypertension Specialised Register, MEDLINE, Embase, ClinicalTrials.gov and the World Health

Full Text available with Trip Pro

2017 Cochrane

169. Pharmacotherapy for hypertension in adults aged 18 to 59 years. (PubMed)

of therapy are in people 18 to 59 years of age.To quantify antihypertensive drug effects on all-cause mortality in adults aged 18 to 59 years with mild to moderate primary hypertension. To quantify effects on cardiovascular mortality plus morbidity (including cerebrovascular and coronary heart disease mortality plus morbidity), withdrawal due adverse events and estimate magnitude of systolic blood pressure (SBP) and diastolic blood pressure (DBP) lowering at one year.The Cochrane Hypertension Information (...) antihypertensive pharmacotherapy with a placebo or no treatment in adults aged 18 to 59 years with mild to moderate primary hypertension defined as SBP 140 mmHg or greater or DBP 90 mmHg or greater at baseline, or both.The outcomes assessed were all-cause mortality, total cardiovascular (CVS) mortality plus morbidity, withdrawals due to adverse events, and decrease in SBP and DBP. For dichotomous outcomes, we used risk ratio (RR) with 95% confidence interval (CI) and a fixed-effect model to combine outcomes

2017 Cochrane

170. Renal denervation for resistant hypertension. (PubMed)

sympathetic ablation (renal denervation) has been recently proposed as a possible therapeutic alternative to treat this condition.We sought to evaluate the short- and long-term effects of renal denervation in individuals with resistant hypertension on clinical end points, including fatal and non-fatal cardiovascular events, all-cause mortality, hospital admissions, quality of life, blood pressure control, left ventricular hypertrophy, cardiovascular and metabolic profile, and kidney function, as well (...) of the evidence was low for cardiovascular outcomes and adverse events and moderate for lack of effect on blood pressure and renal function.In patients with resistant hypertension, there is low quality evidence that renal denervation does not change major cardiovascular events, and renal function. There was moderate quality evidence that it does not change blood pressure and and low quality evidence that it caused an increaseof bradycardia episodes. Future trials measuring patient-centred instead of surrogate

2017 Cochrane

171. Eplerenone for hypertension. (PubMed)

monotherapy versus placebo for primary hypertension in adults. Outcomes of interest were all-cause mortality, cardiovascular events (fatal or non-fatal myocardial infarction), cerebrovascular events (fatal or non fatal strokes), adverse events or withdrawals due to adverse events, and systolic and diastolic blood pressure.We searched the Cochrane Hypertension Specialised Register, CENTRAL, MEDLINE, Embase, and two trials registers up to 3 March 2016. We handsearched references from retrieved studies (...) Eplerenone for hypertension. Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction. It is also used as adjunctive therapy for patients with heart failure following myocardial infarction. Additionally, it is indicated for the treatment

Full Text available with Trip Pro

2017 Cochrane

172. Thiazide diuretic-caused hyponatremia in the elderly hypertensive: will a bottle of Nepro a day keep hyponatremia and the doctor away? Study protocol for a proof-of-concept feasibility trial (PubMed)

Thiazide diuretic-caused hyponatremia in the elderly hypertensive: will a bottle of Nepro a day keep hyponatremia and the doctor away? Study protocol for a proof-of-concept feasibility trial Hypertension is the most common modifiable risk factor for cardiovascular disease, with an increasing prevalence with age, but with easily available medications to control it. Adverse effects of these medications do limit their use, in particular hyponatremia due to thiazide and thiazide-like diuretics

Full Text available with Trip Pro

2018 Pilot and feasibility studies

173. Renin dependent hypertension caused by accessory renal arteries (PubMed)

Renin dependent hypertension caused by accessory renal arteries Hypokalemia in the presence of hypertension is often attributed to primary hyperaldosteronism as a cause of secondary hypertension, however secondary hyperaldosteronism may present similarly. Accessory renal arteries are variants in the vascular anatomy which are often thought to be innocuous but in some circumstances can cause renovascular hypertension leading to secondary hyperaldosteronism.We report 2 cases of hypertension (...) with secondary hyperaldosteronism associated with accessory renal arteries. Both patients presented with hypokalemia and further investigations revealed hyperaldosteronism with unsuppressed renin levels. Imaging studies showed the presence of accessory renal artery.Accessory renal arteries are a potential cause renovascular hypertension which can be detected via CT angiography or magnetic resonance angiography. Hormonal evaluation should be undertaken to determine whether its presence contributes

Full Text available with Trip Pro

2018 Clinical hypertension

174. Albumin-to-creatinine ratio as a predictor of all-cause mortality and hospitalization of congestive heart failure in Chinese elder hypertensive patients with high cardiovascular risks (PubMed)

Albumin-to-creatinine ratio as a predictor of all-cause mortality and hospitalization of congestive heart failure in Chinese elder hypertensive patients with high cardiovascular risks Data are limited with regard to the relationship of albuminuria and major adverse cardiovascular events (MACE) in Chinese elder patients with high cardiovascular risk.We did a retrospective cohort study using Chinese elder patients with high cardiovascular risks (n = 1474) to identify the association of albumin (...) -to-creatinine ratio (ACR) and the incidence of MACE and all-cause mortality. Individuals were followed up from January, 2002 to November, 2007. The all-cause mortality and MACE, composite outcome of cardiovascular death, myocardial infarction, stroke and hospitalization of congestive heart failure were defined as primary endpoint.During the median following up of 56 months, 213 patients developed primary endpoint and 117 patients died. Patients with higher baseline urinary ACR (> 30 mg/g) experienced

Full Text available with Trip Pro

2018 Clinical hypertension

175. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

2017 Prescrire

176. Treatment of Hypertension in Association With Renovascular Disease

is present; however, this caution does not preclude use of these drugs. Most patients will have been treated with a RAAS inhibitor before diagnosis of renovascular hypertension is made or suspected. In randomized controlled trials, such as CORAL, a RAAS inhibitor was a proximal part of treatment protocol . Anticipated soon is inclusion of guidance specific to non-atherosclerotic causes, such as fibromuscular dysplasia, in which estimates of benefit on hypertension outcomes might be larger . Certainly (...) for patients with ostial atherosclerotic renal artery stenosis and renal insufficiency. J Am Soc Nephrol 2001;12:1475-8. Van de Yen PJG, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999;353:282-6. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension

2018 Hypertension Canada

177. Treatment of Hypertension in Association With Diabetes Mellitus

even exceed those of aggressive glycemic control in people with diabetes mellitus for the prevention of cardiovascular complications . Because cardiovascular disease is the most common cause of death in patients with diabetes mellitus , BP control is paramount in these patients. In subjects with diabetes, there is randomized, clinical trial evidence supporting lower BP levels (two major trials are the United Kingdom Prospective Diabetes Study Group [UKPDS]-38 trial and the Hypertension Optimal (...) and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor- associated elevations in serum creatinine. Is this a cause for concern? Arch Intern Med 2000;160:685-93. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic

2018 Hypertension Canada

178. Treatment of Hypertension in Association With Left Ventricular Hypertrophy

drugs. In summary, while antihypertensive therapy improves left ventricular mass and reduces cardiovascular morbidity and mortality in patients with LVH, no one anti-hypertensive class is superior to all others. Most major classes of antihypertensive agents (except direct arterial vasodilators, such as hydralazine or minoxidil) have been shown to cause LVH regression, but not always to the same degree in relation to the amount of BP lowering achieved. Therefore, antihypertensive treatment should (...) Treatment of Hypertension in Association With Left Ventricular Hypertrophy IX. Treatment of Hypertension in Association With Left Ventricular Hypertrophy | Hypertension Canada Guidelines Subgroup Members: Simon W. Rabkin, MD; Gordon W. Moe, MD, MSc; Jonathan G. Howlett, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH

2018 Hypertension Canada

179. Treatment of Hypertension in Association With Nondiabetic Chronic Kidney Disease

Treatment of Hypertension in Association With Nondiabetic Chronic Kidney Disease X. Treatment of Hypertension in Association With Nondiabetic Chronic Kidney Disease | Hypertension Canada Guidelines Subgroup Members: Marcel Ruzicka, MD PhD; Sheldon W. Tobe, MD MScCH; Ramesh Prasad, MBBS MSc MA PhD; Michel Vallée, MD PhD; Cedric Edwards, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc (...) ; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia, BSc MD MSc; Meranda Nakhla, MD MSc Co-Chairs: Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD This information is based on the Hypertension Canada guidelines published in Nerenberg, Kara A. et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. . Recommendations For patients with nondiabetic chronic kidney

2018 Hypertension Canada

180. Treatment of Hypertension in Association With Ischemic Heart Disease

Treatment of Hypertension in Association With Ischemic Heart Disease VI. Treatment of Hypertension in Association With Ischemic Heart Disease | Hypertension Canada Guidelines Subgroup Members: Simon W. Rabkin, MD, Gordon W. Moe, MD MSc, Jonathan G. Howlett, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia (...) Butalia, BSc MD MSc; Meranda Nakhla, MD MSc Co-Chairs: Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD This information is based on the Hypertension Canada guidelines published in Nerenberg, Kara A. et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. . Guidelines Guidelines for hypertensive patients with coronary artery disease (CAD) For most hypertensive patients with CAD, an ACE inhibitor

2018 Hypertension Canada

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>